⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Data S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

Sriram Venneti Abed Rahman Kawakibi Sunjong Ji Sebastian M. Waszak Stefan R. Sweha Mateus Mota Matthew Pun Akash Deogharkar Chan Chung Rohinton S. Tarapore Samuel Ramage Andrew Chi Patrick Y. Wen Isabel Arrillaga‐Romany Tracy T. Batchelor Nicholas Butowski Ashley Sumrall Nicole Shonka Rebecca A. Harrison John de Groot Minesh P. Mehta Matthew D. Hall Doured Daghistani Timothy F. Cloughesy Benjamin M. Ellingson Kévin Beccaria Pascale Varlet Michelle M. Kim Yoshie Umemura Hugh Garton Andrea Franson Jonathan Schwartz Rajan Jain Maureen Kachman Heidi Baum Charles Burant Sophie L. Mottl Rodrigo T. Cartaxo Vishal John Dana Messinger Tingting Qin Erik Peterson Peter Sajjakulnukit Karthik Ravi Alyssa Waugh Dustin Walling Yujie Ding Ziyun Xia Anna Schwendeman Debra Hawes Fusheng Yang Alexander R. Judkins Daniel Wahl Costas A. Lyssiotis Daniel de la Nava Marta M. Alonso Augustine Eze Jasper Spitzer Susanne V. Schmidt Ryan J. Duchatel Matthew D. Dun Jason E. Cain Li Jiang Sylwia A. Stopka Gerard Baquer Michael S. Regan Mariella G. Filbin Nathalie Y.R. Agar Lili Zhao Chandan Kumar‐Sinha Rajen Mody Arul M. Chinnaiyan Ryo Kurokawa Drew Pratt Viveka Nand Yadav Jacques Grill Cassie Kline Sabine Mueller Adam Resnick Javad Nazarian Joshua E. Allen Yazmín Odia Sharon L. Gardner Carl Koschmann

View at Publisher

Ask AI

Bookmark

Share

Abstract

Protocol for NCT03134131, ONC201-018: Expanded Access to ONC201 for Patients with H3K27M-mutant and/or Midline High Grade Gliomas.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Venneti et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523cd2 https://doi.org/10.1158/2159-8290.27026279

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Data S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
2Supplementary Data S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
3Supplementary Data S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
4Table S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
5Table S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024

More related papers

Table S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
Table S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
Table S15 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024